Specialty Pharmacy

Irinotecan liposomal injection (Onivyde) used as second-line therapy for patients with small cell lung cancer did not meet the primary end point of overall survival compared to topotecan.

Narcissistic leaders have a negative impact on the culture of their organization as their conduct and management style induces fear.

Oncology pharmacists must think critically about the digital experience they give patients.

Andrew Barnell, MBA, CEO and co-founder of Geneoscopy, discusses his meeting at the White House on President Biden’s Cancer Moonshot initiative.

Researchers suggest that immune checkpoint inhibitors significantly preserve the quality of life in patients with cancer.

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

FDA approved dexamethasone tablets USP 1.5mg, 4mg and 6mg, providing a new generic alternative to the steroid Decadron.

Gilead Sciences Inc submitted a supplemental Biologics License Application to the FDA for sacituzumab govitecan-hziy (Trodelvy) following promising trial results.

The Oncomine Dx Target Test is a next-generation sequencing–based companion diagnostic developed to analyze 23 genes associated with non–small cell lung cancer in patients who harbor an activating HER2 mutation.

A new study found that reduced tobacco use lowered deaths, person-years of lost life, and lost earnings across many states nationwide.

Zoledronic acid (Zometa) is indicated for the treatment of hypercalcemia that may occur with cancer.

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

Study finds link between higher insulin doses and the risk of developing cancer in patients with type 1 diabetes.

The FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) to treat HER2 mutant non-small cell lung cancer was based on results from the DESTINY-Lung02 phase 2 trial.

New study shows that race does not influence outcomes from immunotherapy for aggressive triple-negative breast cancer.

The Prescription Information Modernization Act seeks to modernize health care with up-to-date digital prescribing information to pharmacists.

Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.

There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.

Organizational culture is determined by how the organizational leadership responds to a crisis, how they adapt to new demands and how they correct an employee when mistakes happen.

Part 3 in a series outlining 5 crucial steps pharmacies can take to enhance patient engagement and lower operational costs.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Use of hormone therapy to treat prostate cancer may require more consideration by health care providers as new study shows the therapy may increase the risk of heart disease.

Based on overall response rate, acalabrutinib in tablet form is now FDA approved for all approved indications, enabling co-administration alongside a proton pump inhibitor.

Dalteparin sodium (Fragmin) is indicated for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce VTE recurrence in adult patients with cancer, as well as several other indications.

The median overall survival of the lenvatinib monotherapy arm is longer than that observed in previous clinical trials evaluating it as a monotherapy for unresectable hepatocellular carcinoma.

Receiving a human papillomavirus vaccine and local surgical treatment could reduce the risk of recurring cervical lesions by 57%.

The FDA approved a new drug that treats unresectable and metastatic HER2-low breast cancer, giving patients with this new subtype a treatment beyond chemotherapy.

Patients can better understand the most current recommendations for breast cancer screening with the new NCCN Guidelines for Patients®: Breast Cancer Screening and Diagnosis.